New class of inhibitor may attack resistance. Potential drug could be cost-efficient.
There is new hope for a cost-efficient treatment for HIV-1 infected patients who no longer respond to protease inhibitor (PI) treatment due to multidrug resistance.
D003362:Cost-Benefit Analysis; D024882:Drug Resistance, Viral / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009154:Mutation
D017320:HIV Protease Inhibitors